ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
简
繁
EN
COMPANY NEWS
Essex Bio-Technology (1061.HK) 2024 Interim Results at a glance
2024.08.26
Essex Bio-Technology Reports 1st H 2024 Net Profit of HK$157.4 Million Poised for Future Success Underpinned by Proven Product Base and Promising Pipeline of Products
2024.08.26
Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024
2024.08.26
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2023-08-16
Essex Bio-Technology (1061.HK) 2023 Interim Results at a glance
2023-08-16
Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%
2023-07-26
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
2023-06-30
EssexBio awarded “2022 China Pharmaceutical Industry Top 100 Series List” and “2023 China Pharmaceutical Brands List”
2023-04-14
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
2023-04-11
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China
2023-03-08
Essex Bio-Technology (1061.HK) 2022 Annual Results at a glance
2023-03-08
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
<
1
2
3
4
5
6
7
...
9
>